Welcome to our dedicated page for Royalty Pharma Plc news (Ticker: RPRX), a resource for investors and traders seeking the latest updates and insights on Royalty Pharma Plc stock.
Royalty Pharma plc (Nasdaq: RPRX) is a biopharmaceutical royalty company that frequently announces transactions, portfolio updates and financial results, making its news flow particularly relevant for investors following royalty-based business models in healthcare. Founded in 1996, the company describes itself as the largest buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry, with a portfolio of royalties on more than 35 commercial products and numerous development-stage therapies.
News about Royalty Pharma often centers on new royalty acquisitions and funding agreements. Recent press releases have described transactions such as acquiring remaining royalty interests in Roche’s Evrysdi, purchasing a royalty interest in Alnylam’s AMVUTTRA from Blackstone Life Sciences, and securing royalty interests in Nuvalent’s neladalkib and zidesamtinib. The company also reports synthetic royalty funding agreements, including a deal with Denali Therapeutics based on future net sales of tividenofusp alfa and a funding agreement with Teva for the anti-IL-15 antibody TEV-‘408 for vitiligo and celiac disease.
Royalty Pharma’s news feed additionally includes quarterly financial results, Portfolio Receipts updates, capital deployment figures, debt offerings, dividend declarations and participation in investor conferences. The company highlights clinical and regulatory milestones across its royalty portfolio, such as FDA approvals, Phase 3 trial initiations and pivotal data readouts for therapies like daraxonrasib, litifilimab, pelacarsen and other late-stage candidates.
Investors and observers who follow RPRX news can use these updates to track how the royalty portfolio is evolving, which therapeutic areas are gaining exposure, and how capital is being allocated across approved and investigational products. Regular news also provides insight into Royalty Pharma’s views on the royalty funding market, its use of non-GAAP liquidity measures, and its approach to shareholder returns through dividends and share repurchases.
Theravance Biopharma announced an agreement to sell its 85% interest in GSK's TRELEGY ELLIPTA royalty rights to Royalty Pharma for over $1.5 billion in potential value, including approximately $1.1 billion upfront. The deal aims to enhance shareholder value by eliminating debt and returning capital. Additionally, Royalty Pharma will invest $40 million to advance ampreloxetine development for MSA. Following the transaction, Theravance expects to have $430 million in cash and aims for breakeven cash flow in the second half of 2022.
Royalty Pharma has acquired an ex-U.S. royalty interest in Gavreto from Blueprint Medicines for up to $340 million, comprising $175 million upfront and $165 million in potential milestone payments. Gavreto is a targeted therapy for certain RET-altered non-small cell lung cancers, approved in Europe since November 2021. This acquisition aligns with Royalty Pharma's strategy to invest in differentiated therapies addressing unmet medical needs. The royalty from Roche is expected to last until 2036 to 2040.
Blueprint Medicines (NASDAQ: BPMC) announced strategic financing collaborations with Sixth Street and Royalty Pharma (NASDAQ: RPRX) worth up to $1.25 billion, enhancing its financial position without shareholder dilution. The deal includes $575 million in cash at closing to support innovations and expand its pipeline, particularly for AYVAKIT and GAVRETO. The structured agreement involves various components, such as royalty monetization and credit facilities, aimed at driving growth in precision therapies for patients.
Royalty Pharma plc (Nasdaq: RPRX) will present at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022, at 2:20 p.m. ET. Interested parties can access the live webcast from Royalty Pharma's Events page, with an archive available for at least 30 days. The company is renowned for being the largest buyer of biopharmaceutical royalties and a key innovator funder, boasting a diverse portfolio of royalties linked to over 35 commercial products including notable therapies like Imbruvica and Xtandi.
Royalty Pharma (Nasdaq: RPRX) will present at the UBS Global Healthcare Conference on May 24, 2022, at 1:15 p.m. ET. The session will be accessible via the company’s Events page and will be archived for thirty days.
Founded in 1996, Royalty Pharma is a leader in purchasing biopharmaceutical royalties and supports innovation in the industry. Its portfolio includes royalties on approximately 35 commercial products, such as AbbVie’s Imbruvica and Merck’s Januvia, as well as multiple development-stage candidates.
Royalty Pharma (RPRX) has increased its five-year capital deployment target to $10-12 billion, reflecting a robust outlook for the biopharmaceutical royalty market. The company anticipates compounded annual growth in Adjusted Cash Receipts of 11-14% from 2020 to 2025, up from a prior forecast of 7-10%. Moreover, Royalty Pharma estimates that demand for capital to fund life sciences innovation could exceed $1 trillion over the next decade. The firm is poised to leverage its strengthened market position to create substantial value for its stakeholders.
Royalty Pharma (RPRX) announced robust Q1 2022 results with net cash from operating activities at $460 million and Adjusted Cash Receipts rising 15% to $605 million. The company reaffirmed its 2022 guidance for Adjusted Cash Receipts set between $2,225 million and $2,300 million. A key highlight includes a $450 million expanded partnership with Cytokinetics for aficamten. Despite a 2% decrease in total income to $562 million, adjusted EBITDA climbed 15% to $556 million. The firm cited strong demand in the cystic fibrosis franchise as a primary growth driver.
Royalty Pharma has announced a dividend payment of $0.19 per Class A ordinary share for the second quarter of 2022.
The payment will occur on June 15, 2022, for shareholders on record by May 20, 2022. This reflects Royalty Pharma's ongoing commitment to return value to shareholders, supported by its robust portfolio of royalties from various leading biopharmaceutical products.
Royalty Pharma plc (RPRX) will report its Q1 2022 financial results on May 5, 2022, before U.S. markets open. A conference call will be held at 8:00 a.m. ET, accessible via phone and webcast. Royalty Pharma, founded in 1996, is a leader in buying biopharmaceutical royalties, with a portfolio covering over 35 commercial products. It collaborates with various innovators to fund clinical trials and product launches, securing future royalties. More details can be found on their official website.
Royalty Pharma plc (Nasdaq: RPRX) has pledged a $7.5 million commitment to The Leukemia & Lymphoma Society (LLS) to tackle healthcare disparities in blood cancer treatment over five years. This funding will support three initiatives aimed at enhancing access to care for underserved communities, including the Equity in Access Research Program, LLS IMPACT Research Grants, and Myeloma Link. Royalty Pharma will not gain any financial return from this charitable contribution, underscoring its commitment to equitable healthcare.
FAQ
What is the current stock price of Royalty Pharma Plc (RPRX)?
What is the market cap of Royalty Pharma Plc (RPRX)?
